Absence of point mutations at codon 17 of the Mdm2 gene (serine 17) in human primary tumors

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 449, Issue 1-2, 2000, Pages 41-45

  Silva, Javier ^a   Silva, Jose M ^a   Dominguez, Gemma ^a   Garcia, Jose M ^a   Rodriguez, Oscar ^a   Garcia Andrade, Carmen ^b   Cuevas, Jesus ^c   Provencio, Mariano ^a   España, Pilar ^a   Bonilla, Felix ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL UNIVERSITARIO SANTA CRISTINA   (Spain)

^c HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

Author keywords

Mdm2 gene; p53 gene; Point mutations; Serine 17

Indexed keywords

DNA DEPENDENT PROTEIN KINASE; PROTEIN MDM2; PROTEIN P53; SERINE;

ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER GENETICS; COLON ADENOCARCINOMA; CONTROLLED STUDY; ENZYME ACTIVATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; TESTIS CARCINOMA; TUMOR SUPPRESSOR GENE;

CODON; GENES, P53; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; POINT MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 0034599952     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(00)00028-2     Document Type: Article

References (31)

1. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a p53 associated protein in human sarcomas. Nature. 358:1992;80-83.
2. Cahilly-Snyder L., Yong-Feng T., Francke U., George D.L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic Cell Mol. Genet. 13:1987;235-244.
3. Fakharzadeh S.S., Trusko S.P., George D.L. Tumorigenesis potential associated with enhanced expression of a gene that is amplified in mouse tumor cell line. EMBO J. 10:1991;1565-1569.
4. Momand J., Zambetti G.P., Olson D.L., George D., Levine A.J. The Mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
5. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., Vogelstein B. Oncoprotein Mdm2 conceals the activation domain of tumor suppressor p53. Nature. 362:1993;857-860.
6. Haupt Y., Maya R., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
7. Kubbutat M.H.G., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 387:1997;299-303.
8. Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimichi A., Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 352:1991;345-347.
9. Lowe S.W., Jacks T., Housman D.E., Ruley H.E. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc. Natl. Acad. Sci. U. S. A. 91:1994;2026-2030.
10. Schlott T., Reimer S., Jahns A. Point mutations and nucleotide insertions in the MDM2 Zinc Finger structure of human tumors. J. Pathol. 182:1997;54-61.
11. Roth J., Dobbelstein M., Freedman D.A., Shenk T., Levine A.J. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17:1998;554-564.
12. Freedman D.A., Levine A.J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell Biol. 18:1998;7288-7293.
13. Leach F.S., Tokino T., Meltzer P., Burrell M., Oliner J.D., Smith S., Hill D.E., Sidransky D., Kinzler K.W., Vogelstein B. p53 mutations and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53:1993;2231-2234.
14. Cordon-Cardo C., Latres E., Drobnjak M., Oliva M.R., Pollack D., Woodruff J.M., Marechal V., Chen J., Brennan M.F., Levine A.J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54:1994;794-799.
15. Reifenberg G., Liu L., Ichinura K., Schmidt E.E., Collins V.P. Amplification and overexpression of the MDM2 gene in a subset of malignant gliomas without p53 mutations. Cancer Res. 53:1993;2736-2739.
16. Momand J., Zambetti G.P. Mdm-2: "big brother" of p53. J. Cell. Biochem. 64:1997;343-352.
17. Ladanyi M., Cha C., Lewis R., Jhanwar S.C., Huvos A.G., Healey J.H. Mdm2 gene amplification in metastasic osteosarcomas. Cancer Res. 53:1993;16-18.
18. Piette J., Neel H., Maréchal V. Mdm2: keeping p53 under control. Oncogene. 15:1997;1001-1010.
19. Mayo L.D., Turchi J.J., Berberich S.J. Mdm2 phosphorylation by DNA-activated protein kinase prevents interaction with p53. Cancer Res. 57:1997;5013-5016.
20. Jackson S.P., Jeggo P.A. DNA double-strand break repair and V(D)J recombination: involvement of DNA-PK. Trends Biochem. Sci. 20:1995;412-415.
21. Anderson C. DNA damage and the DNA-activated protein kinase. Trends Biochem. Sci. 18:1993;433-437.
22. Orita M., Suzuki Y., Sekiya T. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 5:1989;874-879.
23. Oto M., Miyake S., Yuasa Y. Optimization of non-radioisotopic single strand conformation polymorphism analysis with a conventional minislab gel electrophoresis apparatus. Anal. Biochem. 213:1993;19-22.
24. Blaszyk H., Hartmann A., Tamura Y. Molecular epidemiology of breast cancer in northern and southern Japan: the frequency, clustering, and patterns of p53 gene mutations differ among these two low-risk populations. Oncogene. 13:1996;2159-2166.
25. Soong R., Grieu F., Robbins P., Dix B., Chen D., Parsons R., House A., Iacopetta B. p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin. Cancer Res. 3:1997;1405-1411.
26. Schlechte H.H., Schnorr D., Loning T., Rudolph B.D., Mohrt U.M., Loening S.A. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers-investigation by temperature gradient gel electrophoresis TGGE. J. Urol. 157:1997;1049-1053.
27. Lutzker S.G. p53 tumor suppressor gene and germ cell neoplasia. APMIS. 106:1998;85-89.
28. Hayashi K. PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA. PCR Methods Appl. 1:1991;34-38.
29. Finlay C.A. The Mdm2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell Biol. 13:1993;301-306.
30. Satokata I., Tanaka K., Okada Y. Molecular basis of group A Xeroderma pigmentosum: a missense mutation and two deletions located in a zinc finger consensus sequence of the XPAC gene. Hum. Genet. 88:1992;60-607.
31. Little M.H., Prosser J., Condie A., Smith P.J., Van Heiningen V., Hastie N.D. Zinc finger mutations within the WT1 gene in Wilms tumor patients. Proc. Natl. Acad. Sci. U. S. A. 89:1992;4791-4795.